Daniel Brennan, an analyst from TD Cowen, has initiated a new Buy rating on Bio-Techne (TECH).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan has given his Buy rating due to a combination of factors that highlight Bio-Techne’s potential for strong organic growth and margin expansion. Despite macroeconomic risks impacting the stock, Brennan believes the current valuation is undervalued and does not accurately reflect the company’s robust growth opportunities in high-demand areas of life science tools. The company’s portfolio, which is heavily focused on consumables, is regarded highly by customers and is positioned to outperform its peers.
Furthermore, Brennan notes that the consensus growth targets for fiscal year 2026 are reasonable, especially after a year of downward revisions. He anticipates margin recovery as market conditions improve and mergers and acquisitions scale. The expected completion of the Wilson Wolf deal by the end of 2027 is projected to significantly enhance EBIT margins, making the current stock price an attractive entry point for investors. Brennan’s price target for Bio-Techne is set at $65, reflecting his confidence in the company’s future performance.